Monash IVF Group (ASX:MVF) has announced its financial and operational results for the first half of the 2026 financial year, headlined by an underlying net profit after tax of $10.4 million.
The result aligns with previous market guidance despite a slight contraction in total revenue, which dipped 1.8% to $137.9 million compared to the prior corresponding period.
The group's financial performance was impacted by a decision to maintain IVF patient pricing across Victoria, New South Wales, and Queensland, alongside a 11.7% decrease in Australian stimulated cycles.
Group underlying EBITDA fell to $30.2 million, down from $35.6 million in H1 FY25.
However, the international segment provided a growth offset, with stimulated cycles increasing by 6.9%.
Monash IVF remains a dominant force in the Australian market, holding a 19% share and maintaining its status as the only provider with a presence in every mainland capital city.
Clinical outcomes continue to trend upward, with clinical pregnancy rates for women under 43 rising to 40.7%.
The company also reported strong workforce stability, retaining 168 medical specialists and 172 scientists while attracting four new fertility specialists to the group.
Looking ahead, the company is nearing the completion of a major infrastructure transformation.
A flagship new clinic in Brisbane is scheduled for completion in Q4 FY26.
At the time of reporting, Monash IVF Group’s share price was $0.70.